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The aim of this thesis was to investigate the frequency of possibly pathogenic variants in 
the GBA gene in the Finnish population. The main interest was in variants causing Gau-
cher disease. Gaucher disease is the most prevalent lysosomal storage disorder world-
wide. It is an autosomal, recessively inherited disease. The disease is caused by a defi-
ciency of a lysosomal enzyme called glucocerebrosidase which causes the accumulation 
of a substrate, glucocerebroside into lymphoid organs resulting in a wide variety of pheno-
types and symptoms. There are over 200 mutations in the GBA gene known to cause Gau-
cher disease. GBA has also a highly homologous, nearby pseudogene, GBAP1. The ho-
mology and close physical location of GBAP1 also causes difficulties when studying GBA 
as the pseudogene gets easily amplified with the functional gene.  
 
The thesis was carried out in the Institute for Molecular Medicine Finland (FIMM) and con-
ducted as a part of a project of setting up a next-generation sequencing (NGS) panel for 
candidate genes behind various cytopenias. The basis of the study was existing NGS ex-
ome data from three different clinical projects, also conducted at FIMM. The NGS data was 
analyzed regarding the variants found in the GBA gene, the interest being mainly on 
known pathogenic variants and also possible novel variants. The findings were then vali-
dated by use of Sanger sequencing to find out if the variants were actually located in the 
functional GBA gene or its pseudogene, GBAP1. In addition, Sequencing Initiative Suomi 
(SiSu) project data was analyzed for known pathogenic variants. 
 
The results from the validations showed that the presence of the pseudogene affects the 
NGS exome data and can cause false results when analyzing variants in the GBA gene if 
the analysis is made merely based on NGS data. Therefore, GBA specific amplification 
and sequencing is needed in order to verify the true variants in GBA. 
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Työn tarkoituksena oli tutkia GBA-geenin mahdollisten patogeenisten varianttien yleisyyttä 
suomalaisessa väestössä. Pääkiinnostuksen kohteena oli Gaucherin tautia aiheuttavat 
variantit. Gaucherin tauti on yleisin lysosomaalinen kertymäsairaus maailmanlaajuisesti. 
Tauti periytyy autosomeissa peittyvästi. Gaucherin taudin aiheuttaa lysosomaalisen 
entsyymin, glukoserebrosidaasin puutos, joka johtaa substraatin, glukoserebrosidin 
kerääntymiseen imukudoksen elimiin aiheuttaen laajan kirjon erilaisia oireita. GBA-
geenistä on tiedossa yli 200 mutaatiota, joiden tiedetään aiheuttavan Gaucherin tautia. 
GBA-geenin lähistöllä sijaitsee erittäin homologinen pseudogeeni, GBAP1. Pseudogeenin 
samankaltaisuus sekä läheinen sijainti aiheuttavat ongelmia tutkittaessa GBA-geeniä, 
koska pseudogeeni monistuu helposti sen yhteydessä. 
 
Tämä opinnäytetyö suoritettiin Suomen molekyylilääketieteen instituutissa (FIMM) ja tehtiin 
osana projektia, jonka tarkoituksena oli pystyttää uuden sukupolven sekvensointipaneeli 
(next-generation sequencing, NGS) erilaisia sytopenioita aiheuttaville geeneille. Työn 
lähtömateriaalina käytettiin olemassa olevaa NGS-eksomidataa kolmesta eri kliinisestä 
projektista, jotka on tuotettu FIMM:ssä. NGS-data tutkittiin GBA-geenin varianttien 
suhteen, joista kiinnostuksenkohteena olivat jo tunnetut patogeeniset sekä mahdolliset 
uudet variantit. Löydökset validoitiin Sanger-sekvensointimenetelmällä, jotta saatiin selville, 
sijaitsivatko variantit toimivassa GBA-geenissä vai sen pseudogeenissä, GBAP1:ssa. 
Lisäksi Sequencing Initiative Suomi (SiSu) -projektin data analysoitiin tunnettujen 
patogeenisten varianttien osalta. 
 
Validoinnin tuloksista huomattiin, että pseudogeenin läsnäolo vaikuttaa NGS-exomidataan 
ja voi aiheuttaa vääriä tuloksia analysoitaessa GBA-geeniä, jos analyysi tehdään 
ainoastaan NGS-datan perusteella. Tämän vuoksi GBA-geenin varianttien varmistamiseen 
on käytettävä GBA-spesifistä monistusta sekä sekvensointia. 
Avainsanat GBA-geeni, GBA pseudogeeni, GBAP1, Gaucherin tauti, 
NGS 
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Abbreviations 
LSD Lysosomal storage disorder 
GBA Glucosylceramidase beta 
GBAP1 Glucosylceramidase beta pseudogene 1 
NGS Next-Generation Sequencing 
GD Gaucher disease 
SNP Single-nucleotide polymorphism 
ERT Enzyme replacement therapy  
WES Whole exome sequencing 
Exome The protein-coding regions (exons) of a genome as a whole 
dNTP Deoxynucleoside Triphosphate, stands for all four nucleotides, dATP, 
dTTP, dGTP, and dCTP 
HGMD  Human Genome Mutation Database 
ExAc Exome Aggregation Consortium 
dbSNP  The Single Nucleotide Polymorphism Database  
TD PCR Touchdown PCR 
SNV Single-nucleotide variation 
IGV Integrative Genome Viewer 
DM Disease-causing mutation 
FP Functional polymorphism 
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1 Introduction 
Lysosomal storage disorders (LSD) are a heterogeneous group of rare diseases caused 
mainly by a lack of one of the hydrolases. Reduced amount of a specific enzyme results 
in accumulation of the corresponding substrate into lysosomes and causes a vast reper-
tory of various clinical phenotypes. The severity of the disorders vary significantly de-
pending on the particular substrate in question.  
Gaucher disease is the most common lysosomal storage disorder worldwide, and it oc-
curs in between 1:50,000 and 1:100,000 live births in general population. It is estimated 
that GD affects roughly 30,000-100,000 people worldwide. In some populations the dis-
ease occurs more frequently, for example Ashkenazi Jew population where the fre-
quency is as high as 1 in 500 live births. The prevalence of the disease varies between 
populations but seems to be rarer in European origins. In Gaucher disease, the defi-
ciency of glucocerebrosidase causes the accumulation of glucocerebroside into lym-
phoid organs. The enzyme deficiency is caused by mutations in GBA gene. Gaucher 
disease is a type of sphingolipidosis which is a subgroup of LSDs. [1; 7; 11.] 
This thesis was carried out in the Institute for Molecular Medicine Finland (FIMM). The 
topic of the thesis was received from FIMM Genomics department. The aim of the thesis 
was to study the prevalence of possibly disease causing mutations in GBA gene in the 
Finnish population, the interest being especially in variants causing Gaucher disease. 
The study was based on existing NGS exome data from three different projects, also 
carried out at FIMM. The aim was to search for known pathogenic and unknown, novel 
mutations from the existing datasets. The most interesting variants with were validated 
with the use of PCR and Sanger-sequencing to separate the functional GBA from its 
pseudogene and find out if the variants were in fact located in the functional GBA and 
not in the pseudogene. The study was conducted as a part of a project of setting up a 
next-generation sequencing (NGS) panel for candidate genes behind various cytope-
nias.  
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2 GBA gene and its pseudogene GBAP1 
GBA, glucosylceramidase beta, is a protein coding gene located in chromosome 1. GBAs 
cytogenetic location is 1q22 and its genomic coordinates are chr1:155,234,447-
155,244,861 (genome assembly GRCh38/hg38). The GBA gene has 12 exons and 11 
introns [48]. GBA and its pseudogene was first sequenced in 1989. [2; 3.] 
GBAs function is to produce an enzyme called glucocerebrosidase (EC 3.2.1.45), also 
known as glucosylceramidase or D-Glucosyl-N-acylsphingosine glucosyl hydrolase. Glu-
cocerebrosidase is a lysosomal enzyme that plays a factor in glycolipid metabolism by 
hydrolyzing glucocerebroside. Glucocerebroside is a sphingolipid with a glucose head 
group. Glucocerebrosidase enzyme degrades this glycolipid into N-acylsphingosine 
(ceramide) and D-glucose with the presence of H2O (Figure 1). Other chemical names 
for glucocerebroside are glucosylceramide and D-glucosyl-N-acylsphingosine. [2; 3; 4; 
5; 6.] 
 
Figure 1. Hydrolysis of D-glucosyl-N-acylsphingosine (glucocerebroside) into D-glucose and 
N-acylsphingosine. (http://www.genome.jp/dbget-bin/www_bget?rn:R01498) 
Diseases associated with the GBA gene are Gaucher disease and Parkinson’s disease. 
These diseases are mainly caused by point mutations in the coding area of the gene, 
but also insertions, deletions and splice site mutations occur in the gene. There have 
also been studies about correlations between GD and Parkinson’s disease. [7.] 
GBA has a highly homologous pseudogene, GBAP1, approximately 16 kb downstream 
of the functional gene. GBAP1 is a product of gene duplication event that has retained 
the exon-intron -structure of the functional gene. GBAP1 has a 96% sequence homology 
to the exonic area of the functional GBA gene and over 98% homology of the regions 
between intron 8 and 3’-UTR (3’-untranslated region). GBAP1 is approximately 2kb 
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shorter than GBA, missing some Alu-insertions, i.e. repetitive DNA sequences about the 
length of 300bp. [8.] 
The high homology between GBA and GBAP1 enables gene conversion events between 
the two genes. These conversions and unequal crossing over produce recombinant al-
leles, most of them located at the 3’-end after exon 8 of the sequence. Recombination 
alleles usually cause severe forms of GD and has been shown to be lethal in homozy-
gosity in most of the cases. The most common recombination allele is RecNcil which has 
a crossover junction area from intron 9 to exon 10 and as a result a segment of GBAP1 
is incorporated into the functional GBA. The RecNcil allele includes three missense mu-
tations L444P, A456P, and V460V (nucleotide changes [1448T>C;1484G>C;1496G> 
C]).  
The short distance and similarity between GBA and GBAP1 genes causes difficulties 
when studying GBA as the pseudogene is easily amplified with the functional gene when 
using PCR. Hence, GBAP1 has to be first separated from the functional gene to prevent 
false results. [3; 8; 9; 10.] 
3 Gaucher disease 
Gaucher disease (GD) is a rare, autosomal recessively inherited metabolic disorder in 
which glycolipid, glucocerebroside is not degraded properly. The disorder is caused by 
the deficiency of an enzyme called glucocerebrosidase that is encoded by GBA gene. 
The deficiency of the enzyme causes the accumulation of glucocerebroside to lyso-
somes, mainly in macrophages and monocytes, affecting primary and secondary lym-
phoid organs such as spleen, liver, bone marrow and brain. The affected macrophages, 
so called Gaucher cells, cause chronic inflammatory response by activating a number of 
cytokines. [11.] 
There are over 200 mutations in GBA gene that are known to cause GD. Most of them 
are missense point mutations, also called SNPs (single-base polymorphism) that change 
one amino acid to another and alter the structure of the enzyme resulting in loss of func-
tion. Null mutations cause a total lack of enzyme production, which results in more severe 
forms of GD. In most cases, GD is caused by homozygous variations in the GBA. Com-
pound heterozygous variants where the carrier has two different pathogenic mutations 
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are known to cause GD as well and symptoms can vary significantly depending on the 
two variants. The disease is not gender specific and affects both males and females. [7; 
12; 13.] 
The most common pathogenic variant known to cause type 1 GD in homozygous and 
compound heterozygous form, is variant N370S (Figure 2). The homozygous L444P var-
iant has been shown to cause neurological complications that manifest in GD types 2 
and 3. 
 
Figure 2. Four most common pathogenic variants and their distribution among affected indi-
viduals [7]. 
Variants 84GG and IVS2+1 are considered lethal as homozygous because none have 
been found in live born patients. Both variants as compound heterozygous are associ-
ated to type 3 GD. RecNcil recombinant allele that includes three missense mutations 
(L444P, A456P, and V460V) has been found to cause perinatal-lethal form of GD. [7; 9.] 
3.1 Clinical types of Gaucher disease 
GD has been divided into three common clinical types based on the symptoms and onset 
of the disease. The three types vary significantly from the symptoms that they cause. 
There are also two additional subtypes of the disease, perinatal-lethal and cardiovascu-
lar form that can be categorized as distinct forms of the disease.  
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3.1.1 Type 1 GD 
Type 1 GD is called non-neuropathic or non-cerebral form of GD and in most of the cases 
does not affect the primary central nervous system. Type 1 is the most common type of 
GD and more than 90% of patients with the disease have type 1 GD. The course of the 
disease and symptoms may differ substantially between patients, from severe complica-
tions to asymptomatic. Type 1 is also known as the adult form of GD as the symptoms 
usually occur at early adulthood. Symptoms include anemia, bruising due to low amount 
of platelets (thrombocytopenia), decreased amount of white blood cells (leukocytopenia) 
and enlarged spleen and liver (hepatosplenomegaly) (Figure 3). 
 
Figure 3. Severe hepatosplenomegaly in a patient with type 1 GD [15]. 
Also bone abnormalities such as osteopenia or osteoporosis and bone degeneration 
(avascular necrosis) due to loss of blood supply to the bone, are common among patients 
with type 1 GD. Patients usually have almost normal life expectancy depending on the 
severity of the symptoms. [7; 14.] 
3.1.2 Type 2 GD 
Type 2 of GD is known as acute neuropathic or infantile form of the disease. First symp-
toms usually occur in the first 6 months of life and include neurological complications due 
to the accumulation of glucocerebroside in the brain. Other symptoms are enlarged 
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spleen (splenomegaly) and/or liver (hepatomegaly), different types of cytopenias, invol-
untary spasms and seizures and respiratory distress. Some patients with type 2 GD also 
suffer from pulmonary lung disease and difficulty swallowing which results in reduced 
growth velocity and overall development. Patients with type 2 of the disease have a sig-
nificantly shorter life expectancy than normal and patients usually die before 4 years of 
age.  
3.1.3 Type 3 GD 
Type 3 is called chronic or subacute neuropathic form of GD. It is also known as juvenile 
form as onset of the disease is usually during juvenile period. Type 3 is milder form of 
type 2 GD and the course of the disease is slower. Neuropathic symptoms occur also in 
type 3 GD. Other symptoms are anemia, bone abnormalities such as osteoporosis, sei-
zures and difficulties with eye movement (horizontal gaze palsy). Also a significant part 
of patients with GD type 3 develop pulmonary lung disease. Depending on the course of 
the disease, patients usually live well into adulthood but may need assistance with daily 
life as the disease progresses.  
The two other subtypes of GD are perinatal-lethal form and cardiovascular form. Perina-
tal-lethal type is considered a specific form of type 2 GD and differs from it with a few 
specific symptoms. These include non-immune hydrops fetalis in which fluid accumu-
lates into different parts of the fetus and causes swelling due to serious anemia. Also 
skin abnormalities and distinct facial features are common in perinatal-lethal form. Peri-
natal-lethal form is a severe form of GD where the affected usually die while still in womb 
or within first weeks of life. This specific form of GD is caused by homozygous null mu-
tations or recombinant alleles, such as RecNcil [16]. 
Cardiovascular form causes calcification of aortic and mitral valves. Also mild hepato-
megaly may occur. Cardiovascular GD is a distinct form of type 3 GD. [7; 12; 13; 15.] 
3.2 Diagnosis and treatment 
The prognosis of Gaucher disease depends significantly on the course of the disease 
and severity of the symptoms. The diagnosis of GD cannot be made solely based on 
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clinical description because of overlapping symptoms in the different types of the dis-
ease. There are number of tests that are used to verify the diagnosis. The first is meas-
uring glucocerebrosidase enzyme levels in leukocytes or fibroblasts. Reduced enzyme 
levels can indicate Gaucher disease, but other tests are used to confirm the diagnosis 
because enzyme levels can vary considerably between healthy patients as well. Com-
plete blood count (CBC) shows the low levels of blood cells in anemia, thrombocytopenia 
and leukopenia. Imaging with tomography or ultrasonography is used to reveal hepato-
splenomegaly.  
Bone marrow biopsy is used to review the changes in macrophages. Gaucher cells (Fig-
ure 4) have distinct features such as abnormal placement of nucleus and cytoplasm that 
resembles “wrinkled tissue paper”. Genetic testing of patients and relatives is used to 
determine the specific mutations in the GBA gene. 
 
Figure 4. White arrows pointing the Gaucher cell. Blue arrow showing the placement of nu-
cleus and red arrow pointing at wrinkled cytoplasm [15]. 
Treating patients with GD is often difficult due to the variability of symptoms between 
patients. Enzyme replacement therapy (ERT) is the most common treatment of GD and 
has been shown to be effective especially to patients with type 1 GD by reversing symp-
toms like hepatosplenomegaly and bringing blood cell counts to normal level. Also skel-
etal problems can be treated with ERT, but the response time has been shown to be 
longer. ERT is well tolerated and only a small fraction of patients produce antibodies 
against the enzymes given. Gaucher disease was the first LSD to be treated with ERT. 
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Substrate reduction therapy (SRT) can be used in addition to ERT that can further en-
hance the effect of ERT. In SRT the formation of substrate, glucocerebroside is reduced 
with inhibitors. On rare occasions, bone marrow transplantation (BMT) may be needed 
if ERT is not an option. Due to the morbidity and mortality of BMT, it is not used widely 
anymore for treating GD. 
A number of patients with GD may also need surgical care. Splenectomy was once a 
common treatment for splenomegaly in GD, but due to ERTs success, it is now per-
formed only in specific cases where the spleen is severely enlarged or in a risk of rapture. 
Patients with serious bone disease can also need hip replacements and other skeletal 
procedures. 
The problem with treating GD patients with types 2 and 3 of the disease is that neuro-
logical complications cannot be reversed with ERT. Also, most drugs are unable to cross 
the blood-brain barrier (BBB) which complicates drug distribution to the brain. [6; 14; 16.] 
 
There are several treatment methods under investigation for GD and other LSDs. One 
of them is pharmacological “chaperones”, chemical compounds that bind to the active 
site of the enzyme and stabilize the structure. As a result, more of functional enzyme is 
transferred to lysosomes. One of the advantages of chaperone therapy is that it enables 
chemical distribution to the brain by penetrating the BBB due to the small size of the 
compound. For that reason, chemical chaperones might be the future treatment for types 
2 and 3 GD. [18; 36.] 
4 NGS exome workflow (Illumina) 
Genetic testing is widely used in diagnosis of genetic disorders, such as Gaucher dis-
ease. The newest method used for genetic testing is Next-generation sequencing (NGS). 
NGS is a high through-put sequencing system that enables fast and accurate sequenc-
ing on a larger scale than Sanger-sequencing. NGS offers many applications, for exam-
ple, WGS (whole genome sequencing), exome sequencing, targeted sequencing panels 
and RNA-sequencing.  
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Targeted sequencing can be used when the interest is on a specific set of regions or 
genes. One of the NGS applications is Whole Exome Sequencing (WES) where the tar-
gets are the protein-coding regions of the genome. The exome covers approximately 1% 
of the whole human genome, but this portion of the genome is responsible for all the 
protein production in our system. The majority of pathogenic mutations are located in 
exons, which makes WES a popular application for NGS. The exome is targeted using 
a target enrichment method where the exons are captured with specific probes and the 
target is then amplified and sequenced. WES is more cost-effective compared to WGS 
if the particular targets of interest are known. With WES the sequencing depth can also 
be adjusted to the level where even the rarest variants can be detected. [22.] 
Illumina Inc. (San Diego, California, United States) is the most widely known and applied 
NGS platform. The sample library preparation workflow of Illumina’s WES and targeted 
gene panels follow the same guidelines and steps as any NGS application by Illumina. 
The following overview of targeted exome sequencing will cover library preparation and 
sequencing of paired-end libraries using Illumina’s platform. Sequence capture is carried 
out by hybridization with oligonucleotide probes.  
4.1 Library preparation 
Sample library preparation for NGS consist of fragmentation, end-repair, A-tailing and 
ligation. In fragmentation, the genomic DNA (gDNA) sample is degraded into smaller, 
approximately 250-350 bp long fragments. Fragmentation is done with acoustic shearing 
or focused sonication. End-repair enzyme T4 DNA polymerase, which has a 5’->3’ poly-
merase and 3’->5’ exonuclease activity, then removes single stranded overhangs from 
the double stranded DNA fragments to form blunt ends and simultaneously phosphory-
lating the 5’-ends of the fragments.  
In A-tailing, Klenow fragment, N-terminal domain of DNA polymerase 1 from E. coli, adds 
dAMP (A-base) to the 3’-end of the fragment [28]. This enables ligation of Y-adapters 
with complementary dT-overhangs at the ends of the fragment. In ligation, T4 DNA ligase 
enzyme catalyzes a phosphodiester bond between 5’-phosphate and 3’-hydroxyl ends 
of the fragments and adapters. Adapters contain index tags that act as identification se-
quences for each sample. In paired-end sequencing the adapters are ligated to both 
ends of the fragment (Figure 5). Special tails, called P5 and P7 are also added to each 
sample fragments. These tails attach to the complementary oligos on the surface of a 
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flowcell during cluster generation. After ligation the sample library is then amplified. After 
every step of the sample library preparation (fragmentation, end-repair, A-tailing and li-
gation), the sample is purified, for example, with magnetic beads, to dispose of impurities 
such as remaining enzymes. 
 
Figure 5. Complete indexed sample library [20]. 
An alternative method for sample library preparation is tagmentation by Nextera (Nextera 
DNA Sample Prep Kit, Illumina) where transposase enzyme fragments the gDNA and 
adds adapters to the ends of the fragment, simultaneously in one tube. Prepared library 
is then amplified and indexed using PCR. Nextera takes considerably less time com-
pared to traditional library preparation. [19; 22; 23; 24.] 
As mentioned above, in WES the exons of a genome are captured with specific probes 
that are biotinylated. This is called target enrichment and is carried out by hybridizing the 
probes to the target. The probes for WES are included in kits intended for exome se-
quencing. Depending on the manufacturer of the kit, the prior ligated adapters are usually 
blocked with complementary oligos to prevent adapter-dimer formation. Also known re-
petitive elements, such as Alu-sequences, are blocked using COT human DNA, for more 
efficient and accurate results. After probe hybridization, the target is captured with mag-
netic streptavidin beads that attach to biotin on the probes. By use of the magnetic beads, 
the target can be separated from the off-target fragments and the excessive products 
are washed away.  
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4.2 Cluster generation 
Prior to sequencing, the previously captured and enriched targets are attached to the 
surface of a flowcell that contains oligos complementary to P5-/P7-tails that act as se-
quencing primers. The sequence template attaches to the P7-tail on the flowcell. Com-
plementary sequence is then synthesized after which the original template is cleaved off, 
leaving only the newly formed complementary sequence attached to the flowcell. The 
sequence is amplified with bridge amplification where the open end of the template 
curves over and is attached to P5-oligo on the flowcell (Figure 6). Complementary strand 
is created during amplification and after denaturation the two templates can be cleaved 
from one end of the flowcell, creating two single stranded copies of the template. These 
two sequences then curve over again and bind to the complementary oligos creating 
more copies of the template. After amplification, the complementary reverse strands at-
tached to the P5-oligo are denatured and removed. As a result, only the forward tem-
plates attached to P7-oligos are left on the flowcell. [26.] 
 
Figure 6. Cluster generation by bridge amplification. A) The template is attached to the P7-
tail on the surface of the flowcell and complementary sequence is synthesized and original 
template removed. B) The complementary strand curves over and attaches to P5-tail and 
complementary sequence is created. The two strands are denatured leaving single stranded 
copies of the template on the flowcell. C) Complementary reverse strands are cleaved and 
only forward templates are left on the flowcell attached to P7-tails. The P5-oligos are blocked 
and sequencing primers are attached to the adapters [26]. 
The formed groups of template clones are called clusters. One cluster consists of roughly 
1,000 copies of the fragment. Clusters are detected through imaging and can be sorted 
out based on their indexes. Cluster generation is done either within the sequencer (e.g. 
Illumina’s HiSeq1500) or in a separate instrument, cBOT (Illumina) that primes the 
flowcell and amplifies the sequence templates. 
A      B      C
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4.3 Sequencing and Data analysis 
NGS technique utilizes sequencing by synthesis-method (SBS), where fluorescently la-
beled dNTPs (A, T, G, C) are synthesized on to the sequence template one by one. The 
sequencing templates and free oligonucleotides are blocked from 3’-end to prevent un-
specific binding. Sequencing primers are hybridized to the adapters attached to the tem-
plates. Nucleotides are reversible terminator-bound dNTPs which means that their 3’-
OH groups have been blocked. During every sequencing cycle, one dNTP is hybridized 
independently to the template after which the fluorescent emission of the dNTP is de-
tected by laser. The OH-block is then cleaved and another dNTP can be hybridized to 
the sequence. This technique greatly reduces sequencing bias and unspecific bonding 
of dNTPs. In paired-end sequencing the sequence template is read from both ends. Be-
fore the second sequence read, the cluster is re-synthesized. The template bridges over 
and is attached to P5-oligo. A sequence is synthesized and denatured, as before, after 
which the original template is cleaved and washed away. All of the synthesized templates 
are now attached to P5-oligo. This enables the second sequence read from the other 
end of the template. One read is produced per each cluster on the flowcell, paired-end 
sequencing produces two reads. 
Sequencing depth means the average amount of reads produced per template, for ex-
ample, 30x generates an average of 30 reads per template. The depth can be adjusted 
to accommodate different objectives. The deeper the sequencing depth, the better the 
specificity and sensitivity to detect variants [27].  
In data analysis, the different reads are aligned to a reference genome. From the align-
ment, different variations, such as SNPs and indels (insertion-deletion), can be identified. 
Alignment and data analysis is carried out by different data analysis pipelines. [22; 25.] 
Following the data analysis, the possible findings from the data need to be validated with 
a different method to verify the results due to the potential misleading analysis of the 
pipelines. A method commonly used for validations is PCR amplification followed by 
Sanger-sequencing.  
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5 Materials and Methods 
5.1 NGS Exome Data 
The data used in this study was produced at the Institute for Molecular Medicine Fin-
land (FIMM). The data consisted of existing next-generation sequencing exome data 
from three different projects that had been sequenced at FIMM Sequencing Unit. The 
three projects were FHRB, ClinPIDD and Myeloma. All three projects are investigating 
hematological diseases or related deficiencies.  
FHRB (Finnish Hematology Registry and BioBank) include a collection of samples from 
different fields of hematology and from patients that express similar symptoms as in Gau-
cher disease. ClinPIDD project is comprised of patients with primary immunodeficien-
cies, PIDDs, with possible overlapping symptoms with hematological disorders. The 
PIDDs consists of a various group of disorders that affect the immune system and usually 
manifest in the first year of life [29]. The myeloma project consist of patients with suspi-
cion for myeloma which is a cancer of the plasma cells. As the cancer affects the blood 
cells it can manifest similar symptoms to GD, such as anemia and bone disease. The 
sample amount of the study was >450 samples in total, the majority consisting of 
ClinPIDD patients.   
In addition to the three projects, data from the SiSu project (Sequencing Initiative Suomi) 
was included in the study. SiSu is an international collaboration project with an aim build 
databases and tools for research utilizing the Finnish inheritance. The project includes 
whole genome and exome sequencing data from >10000 samples that have been se-
quenced for different disease-specific and Finnish population genetic studies. The SiSu 
project is coordinated in FIMM [47].  
NGS exome workflow was performed following Roche Nimblegen SeqCap EZ library SR 
capture technology using Illumina’s HiSeq1500 and HiSeq2500 sequencers at FIMM Se-
quencing Unit. SeqCap EZ MedExome Enrichment kit (Roche Holding AG, Basel, Swit-
zerland) or Agilent SureSelect Clinical Research Exome kit (Santa Clara, California, 
United States) was used to capture the targeted exons [20]. 
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5.2 Data analysis 
Annotation files were created from the NGS exome data by use of various scripts in Unix 
environment using Putty [41]. Gene annotation is a sequence information file that ena-
bles the analysis of raw sequencing files. In creating annotation files, the sequencing 
data is aligned to reference genome which gives specific locations for each of the vari-
ants found. Based on the location of the variant and information from various databases, 
the gene annotation gives information on the variants functionality, whether it is a point 
mutation, deletion, insertion or splice site mutation and gives predictions of a variants 
pathogenicity and possible consequences for protein structure. The annotation file in-
cludes all variants found in genes that are included in the target. [30.] 
The regions and variants of interest, in this case the interest being in the GBA gene, 
were extracted from the annotation files created. The extraction was done using grep-
command in Putty. Grep-command enables the extraction of specific lines, in this case 
lines with gene name GBA, from large annotation files. Scripts used in creating annota-
tion files and using grep-command can be seen in Appendix 1. 
From the extracted annotation files, now consisting of only GBA gene variant information, 
all the variants and their prediction of pathogenicity was first checked from HGMD (Hu-
man Genome Mutation Database) based on their rs-number and start location in the 
genome [31]. Genomic start location was used as well, because a portion of the variants 
lack rs-numbers. The interest was particularly in exonic, nonsynonomous variants. The 
possibly pathogenic variants and other interesting variants were then researched from 
other databases, such as ClinVar, ExAc (Exome Aggregation Consortium) and dbSNP 
[32; 33; 34]. The unknown variants (not found in HGMD), especially exonic and splicing 
variants without rs-number, were also searched from databases mentioned above to find 
out if they were novel and possibly disease causing. The data was also analyzed in re-
spect of both homozygous and compound heterozygous variants, as GD being a reces-
sively inherited disorder can be caused either by homozygous or compound heterozy-
gous mutations. 
The SiSu project data was searched for known pathogenic mutations from the unre-
stricted data from the internet site. All of the listed variants in the GBA gene were first 
extracted from the internet site and then searched from HGMD on the basis of their rs-
number or start location. The variants belonging to disease-causing mutation variant 
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class DM (according to HGMD) were further checked from ClinVar and ExAc to get more 
information on their prevalence and clinical significance [32; 33]. Original literature refer-
ences from HGMD were also evaluated in order to determine the pathogenicity of the 
found variants.  
5.3 Validations 
The purpose of the validation was to find out, by use of another method, if the variants 
found from the patients were in fact located in the functional GBA gene or in its pseudo-
gene, GBAP1. The NGS data analysis pipelines are unable to differentiate in which of 
the highly homologous genes the variants are located. For this reason, the validations 
have to be done manually by use of PCR and Sanger-sequencing. 
5.3.1 Touchdown PCR  
The primers used in the validations were designed to unique locations in GBA gene using 
Primer3 [49]. The GBA gene was amplified in two parts because the length of the gene 
did not allow amplification as one fragment (Table 1). GBA_1-segment covers exons 6-
12 (3’-end) and GBA_1 exons 1-7 (5’-end). Long-range PCR and GBA specific primers 
were used in order to separate the functional GBA gene from its pseudogene. Phusion 
High-Fidelity protocol and Master Mix (New England BioLabs Inc, (NEB), Ipswich, Mas-
sachusetts, United States) was used in the amplifications according to the manufac-
turer’s instructions [37]. 
Table 1. Primers for GBA PCR amplification in two parts. 
 
Touchdown PCR (TD PCR) program was previously optimized with FIMM internal control 
sample, FimmX. In TD PCR, the annealing temperature is decreased progressively at 
each PCR cycle. This reduces primer-dimer production and optimizes the target template 
amplification as unspecific products form usually in lower temperatures [38]. Extension 
time was extended to 4 minutes due to the long product sizes of the two amplicons 
Primer-F Primer-R Product size (bp) Coordinates
GBA_1 CACAGACCCACACAGAGACT TTCACCGCCTATCATCTGCT 5958 chr1:155202693-155208650
GBA_2 CTTGAGTGACCCCTTCCCAT GTGTGCTGGCGGGAAAAC 6743 chr1:155207975-155214714
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(Phusion protocol: extension time 15-30s/kb). Touchdown temperature range was deter-
mined at 72 °C to 60 °C, decreasing 1 °C at each cycle (Table 2). Negative control, or 
no template control (NTC) and FimmX samples were used to see if there are any con-
taminations or other errors in any of the reactions. PCR reactions were done using GS4 
multi block thermal cycler (G-Storm, Somerset, United Kingdom). 
Table 2. PCR reaction mix (Phusion) and Touchdown PCR program. 
 
The results from the PCR were verified with a LabChip GX –instrument (PerkinElmer, 
Waltham, Massachusetts, United States) using genomic DNA -kit to see if the formed 
product was the right size and if there were substantial amounts of primer-dimer that 
needed to be purified prior to sequencing. The reaction was done by following Perki-
nElmer’s Genomic DNA LabChip GX User Guide [39]. 
The PCR product was purified with NucleoMag magnetic beads (NucleoMag NGS Clean-
up and size select, Macherey-Nagel, Dueren, Germany) following the manufacturer’s 
protocol. The ratio between PCR-product and magnetic beads was 1:1 of the volume. 
The sample was eluted to 20 µl of PCR grade water. 
Reagent 1x
2x Phusion MM (1x) 10 µl
Primer F (0,5 µM) 2 µl
Primer R (0,5 µM) 2 µl
DNA (20 ng/µl) 1 µl
H2O 5 µl
Total volume 20 µl
TD-PCR program
Denaturation 1. 98°C, 30s
Annealing 11 cycles 2. 98°C, 10s
3. 72-60°C, 30s
4. 72°C, 4min
Annealing 17 cycles 1. 98°C, 10s
2. 60°C, 30s
3. 72°C, 4min
Elongation 4. 72°C, 10min
5. 10°C, ∞
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All of the PCR products were concentrated from 20 µl to 10 µl to improve the quality of 
the Sanger-sequencing results. The concentration was performed using DNA Clean & 
Concentrator™-5 –kit by following the protocol (Zymo Research, Irvine, California, 
United States). 
5.3.2 Nested Sanger-sequencing 
In nested Sanger-sequencing the previously amplified PCR product was used as a tem-
plate. The specific targeted variants were then covered by sequencing with nearby pri-
mers. The primers were designed using Primer3 and cover all the 12 exons of GBA gene. 
The primer locations used in nested Sanger-sequencing were visualized using Integra-
tive Genome Viewer (IGV) that images the variants and primers to the target gene with 
the coordinates imported to the software [40]. The nearest primers to the variants were 
chosen for nested sequencing.  
Sanger-sequencing was done using the BigDye Terminator v3.1 Cycle Sequencing Pro-
tocol and Kit (Thermo Fisher Scientific, Waltham, Massachusetts, United States). The 
dilution factor for BigDye was 8 (1:8 mix) and was determined on the basis of previous 
testing. The sequencing reaction mix can be seen in Table 3. 
Table 3. Sanger-sequencing reaction mix using BigDye. 
 
Purification was done with Performa DTR v3 filter plates to remove the leftover dye ter-
minator. The template size to be sequenced was set to >800 bp to ensure that all the 
variants will be covered by sequencing. The templates were sequenced with ABI3730xl 
DNA Analyzer (Applied Biosystems, Foster City, California, United States) [42]. 
1x 1:8 mix
Water 4,85 µl
Seq.Buffer (0,75x) 1,5 µl
BigDye (0,25x) 1 µl
Total 7,35 µl
MIX 7,35 µl
PCR 2 µl
primer  (3,25 pmol) 0,65 µl
Total volume 10 µ
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6 Results and conclusions 
6.1 Variant selection for validation 
In the analysis of FHRB, ClinPIDD and Myeloma exome data, five SNP variants were 
found that had some obscurity of their pathogenicity. All the variants of interest were 
found to be heterozygous. Only the most prevalent intronic or intergenic variants were 
present in homozygous state, which was not considered to be a cause for concern as 
they were known to be benign. Compound heterozygosity of variants was not detected 
in the samples either. The selected variants for further examination, their function, nu-
cleotide variation and frequencies from different databases can be seen in Table 4 and 
Table 5. 
Table 4. Variants selected for validation.  
SNP Variant class (HGMD) Ref Alt Function Exonic Function 
rs2230288 DM? C T Exonic Nonsynonomous SNV 
rs188978150 FP T C Intronic NA 
rs75548401 DM? G A Exonic Nonsynonomous SNV 
rs555143723 NA C G Splicing  NA 
rs150466109 DM? T G/C Exonic Nonsynonomous SNV 
The specific variants were selected for validation based on HGMDs variant class speci-
fications, DM? and FP (Table 4). Variant classified as DM? implies to a likely pathogenic 
mutation, but some degree of doubt has been indicated on its pathogenicity. FP variant 
is an in vitro or in vivo functional polymorphism that has been reported to affect the struc-
ture or function of the gene and possibly affect the gene product. This variant class in-
cludes promoter variants, such as rs188978150, that have been shown to affect the pro-
moter function by reducing its activity. This variant has not yet been associated to GD, 
but according to HGMD, variants such as this should always be viewed with caution [31]. 
A rare and not yet well-known splicing variant, rs555143723, was found in ExAc data-
base based on its starting location (Table 4 and Table 5). This variant was selected also 
for validation among the other variants.   
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Table 5. Selected variants: their frequencies and phenotypes based on different databases. 
SNP Variant class (HGMD) ClinVar 
ExAc Freq. 
(homozygous) 
dbSNP  
frequency  
rs2230288 DM? Benign 0.009792 (12)   
rs188978150 FP promoter variant NA NA 0.0159000 
rs75548401 DM? Uncertain significance 0.006571 (6)   
rs555143723 NA NA 0.00005875 (0)   
rs150466109 DM? Benign 0.007052 (23)   
Three of the selected variants were exonic, nonsynonomous SNVs (Table 4). Nonsyn-
onomous variations are missense point mutations that change one amino acid to another 
and affect the structure of the encoded protein [35]. One of the two others was an intronic 
variant (rs188978150) and the other a splicing variant, rs555143723 (Table 4). All the 
validated variants were single base substitutions. 
6.2 SiSu project 
There were 8 variants found from the 10,000 samples of SiSu project data that were 
considered to be disease-causing mutations by HGMD [31]. The variants found in the 
data, their location, prevalence according to ExAc and clinical significance based on 
ClinVar can be seen in Table 6. Also the heterozygous carrier amount and type of GD 
caused by the specific variant are listed on table below (Table 6). The reference infor-
mation for variant rs760307559 was not available. 
Table 6. Disease-causing mutations found from SiSu data. 
 
Most of the listed disease-causing variants, based on HGMD, were found also from Clin-
Var and ExAc databases [32; 33]. According to the reference information of the variants 
in HGMD, all of the variants were reported as pathogenic in original articles. For example, 
first variant on the list (the variant lacks rs-number) was not found in either ClinVar or 
Variant Position Annotation HGMD Het. (N) ClinVar ExAc (freq) Type GD
NA 155205105 SPLICE_SITE DM 1 NA NA 3
rs104886460 155210420 ESSENTIAL_SPLICE_SITE DM 1 pathogenic 0.0001154 1, 3
rs364897 155208006 NON_SYNONYMOUS_CODING DM 1 pathogenic 0.00006813 1
rs369068553 155204996 NON_SYNONYMOUS_CODING DM 2 NA 0.0000659 1
rs381737 155207932 NON_SYNONYMOUS_CODING DM 1 pathogenic 0.0000164 3
rs421016 155205043 NON_SYNONYMOUS_CODING DM 34 pathogenic/likely pathogenic 0.003099 2, 3
rs760307559 155206076 NON_SYNONYMOUS_CODING DM 1 NA NA -
rs76763715 155205634 NON_SYNONYMOUS_CODING DM 18 pathogenic, risk factor 0.00221 1
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ExAc, but in the reference article, the variant was defined as existing as a compound 
heterozygous variant in patients with GD. The two detected heterozygous variants were 
c.762-1GNC(IVS6-1GNC) and c.1389-3CNG(IVS9-3CNG) and were said to cause type 
3 GD [43]. Another variant, rs104886460 was listed as compound heterozygous in the 
original article. The other variant was a common N370S mutation that is known to cause 
type 1 of GD [44]. Variant rs76763715 was found both as homozygous and compound 
heterozygous based on the reference information. The variant causes type 1 GD. [45] 
Two of the listed variants, rs421016 and rs76763715 prevalence was quite high in ExAc 
which also translated to the carrier amount of the variants in the SiSu data. The other 
variants in the list were rare and only one heterozygous carrier was found for each vari-
ant. All of the variants were detected in heterozygous state in SiSu data. Due to the 
limited access to data, it was not possible to analyze if the carriers were compound het-
erozygous for the detected GBA variations. The projects samples were not available for 
further analysis; therefore, validations of the findings could not be performed from the 
SiSu project. 
6.3 Long-range Touchdown PCR 
All of the selected variants were validated from two different samples. The samples used 
for validation and the amplified part of GBA can be seen in Table 7. 
Table 7. Location of variants, samples for validation and PCR amplified part of GBA. 
SNP Samples PCR 
rs2230288 PID207, FHRB_5240 GBA_1 
rs188978150 PID123, PID230 GBA_2 
rs75548401 PID231, PID232 GBA_1 
rs555143723 PID087, PID088 GBA_2 
rs150466109 PIDD235, PIDD343 GBA_2 
The program used for TD PCR can be seen in Materials and Methods section of the 
thesis. The success of the PCR was determined with the LabChip GX instrument using 
genomic DNA kit. The PCR products were diluted to 1:10 of PCR grade water. Lower 
marker, LM can be seen at 0.0 on horizontal scale in all of the samples. 
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Samples ClinPIDD207, FHRB5240, ClinPIDD231 and ClinPIDD232 were amplified using 
GBA_1 primers as they all were located in exon 9. The product size for GBA_1 should 
be around 5.9 kb. The multiple overlay electropherogram shows that approximately the 
right size product was amplified from all four samples (Figure 7). 
 
Figure 7. LabChip GX results from samples ClinPIDD207 (blue), FHRB5240 (red), 
ClinPIDD231 (brown) and ClinPIDD232 (green) amplified regarding amplicon GBA_1. 
The product amplified from sample ClinPIDD231, shown in green, seemed to be a bit 
longer than the other samples but could be due to the x-axis scale not being linear. In all 
of the samples, primer-dimer was formed that needed to be washed away with purifica-
tion as smaller products may interfere in the sequencing reactions. Primer-dimer can be 
seen at 0.1 peak in all of the electropherograms. The most amount of primer-dimer was 
formed from sample ClinPIDD207 (blue) and also the least amount of actual product was 
amplified from mentioned sample. The most amount of product was amplified from sam-
ple ClinPIDD231 (brown line). Samples FHRB5240 and ClinPIDD207 produced quite 
small amounts of product which may affect the success of nested sequencing as the 
PCR sample could be too diluted.  
Samples ClinPIDD123, ClinPIDD230, ClinPIDD087, ClinPIDD088, ClinPIDD235 and 
ClinPIDD343 were amplified with GBA_2 primers (Figure 8). Also in this case, all of the 
amplified products were nearly the same size. The covered product size was 6.7 kb and 
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results show that the right size product was amplified from all six samples. As with 
GBA_1, primer-dimer was formed in all of the samples. The least amount of product was 
amplified from sample ClinPIDD87 which can be seen in blue in the overlay electrophe-
ogram. Substantial amount of primer-dimer was formed from sample ClinPIDD123 (red) 
and ClinPIDD230 (turquoise). The most amount of product was amplified from 
ClinPIDD88 (brown). As with GBA_1, some of the GBA_2 samples were not amplified 
efficiently, which may affect the performance of the sequencing reaction. 
 
Figure 8. LabChip GX results from samples ClinPIDD087 (blue), ClinPIDD088 (brown), 
ClinPIDD123 (red), ClinPIDD230 (turquoise), ClinPIDD235 (green) and ClinPIDD343 (pink) 
amplified regarding amplicon GBA_2. 
Samples ClinPIDD087, ClinPIDD088, ClinPIDD123, ClinPIDD235 and ClinPIDD343, 
shown in Figure 8, were amplified with a different TD PCR range, 72 °C to 62 °C, de-
greasing 1°C per cycle which optimized the product amplification and also decreased 
the amount of primer-dimer.  
FimmX control sample was amplified in both fragments of the gene, GBA_1 and GBA_2 
(Figure 9). Blue line shows GBA_1 and red line GBA_2. Based on the results, the right 
size products, 5.9 kb and 6.7 kb, were amplified from both GBA fragments, GBA_2 frag-
ment being approximately 0.8 kb bigger than GBA_1. GBA_2 was amplified more com-
pared to GBA_1 but also a substantially more primer-dimer was formed. GBA_2 from 
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FimmX was amplified using TD PCR program with a range of 72 °C to 62 °C, as well, 
because it produced more of the desired product and less primer-dimer. 
 
Figure 9. LabChip GX results from FimmX sample amplified regarding both amplicons, 
GBA_1 (blue) and GBA_2 (red). 
Negative control, NTC shows that no contamination occurred in the reactions as no 
peaks has been formed in the electropherograms (Figure 10). The NTC sample was 
amplified in all reactions to find out if any of the primers may have been contaminated. 
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Figure 10. LabChip GX results from negative control, NTC sample amplified regarding 
GBA_1 and GBA_2.  
6.4 Nested Sanger-sequencing results 
The sequencing primers to be used were determined with IGV, as mentioned in Materials 
and Methods-section [40]. The imaging showed that two of the variants, rs2230288 and 
rs75548401 were located in exon 9 (Table 8). Two others, rs188978150 and 
rs555143723 could be covered with exon 2 primers and the fifth variant, rs150466109 
was located in exon 3. The variants were sequenced using forward and reverse primers. 
The intronic variant, rs188978150 was sequenced using only exon 2 reverse primer as 
the designed primers target primarily only the exonic areas of the GBA gene and only 
the reverse primer could cover the targeted SNP. 
 Table 8. Primers used for nested sequencing determined with IGV. 
SNP Sequencing primers Primer-F Primer-R 
rs2230288 exon_9 tcagtagttgcaaaaggggc cagcccgagtgacagagtg 
rs188978150 exon_2-R - tggccctggattcaaagaga 
rs75548401 exon_9 tcagtagttgcaaaaggggc cagcccgagtgacagagtg 
rs555143723 exon_2 cgggaagccggaattacttg tggccctggattcaaagaga 
rs150466109 exon_3 gaggggcttgcttttcagtc ggaggcagaggttggaatga 
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The results from nested Sanger-sequencing were verified by use of Sequencher 4.8- 
software. The sequence AB-files of the sequenced fragments, fasta-sequences of exons 
and sequences surrounding the variants were imported to the software which then aligns 
them to a single contig-file. The fasta-sequences of the variants were searched from 
dbSNP [34]. After the sequence alignment, the variants were searched from the chro-
matograms of the sequenced samples. 
The reverse primers were discovered to work better and produced cleaner sequencing 
results than the forward primers. Chromatograms from reverse primers had also less 
background interrupting the analysis compared to chromatograms from forward primers. 
Therefore, reverse sequences were used for analysis of the Sanger-sequencing results. 
The samples FHRB5240 and ClinPIDD207 were sequenced regarding the variant 
rs2230288. According to the NGS exome data both of the samples were heterozygous 
for the variant. The results from the nested Sanger-sequencing showed a Y-base, 
marked with a black box,  on both of the sequences which indicated that the patient had 
a T base on one allele and an alternative base C, SNP variant, on the other (Figure 11). 
 
Figure 11. Sanger-sequencing results for SNP rs2230288 from samples PID207 (above), 
FHRB5240 (middle) and FimmX control (below). 
Chromatogram results from control sample FimmX showed reference base C (below). 
Comparing the peaks from FimmX and the samples, the Y-bases found from the two 
samples were lower compared to the height of C-base from FimmX which also indicated 
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heterozygosity in both FHRB5240 and ClinPIDD207 samples. Both FimmX and 
ClinPIDD207 samples had a bit of background coming through in the chromatograms 
but not enough for it to interfere with the interpretation of the results. The results con-
firmed that both of the patients are heterozygous concerning SNP rs2230288 and that 
the variant is in fact located at the functional GBA gene on both samples. Therefore, the 
Sanger-sequencing results verify the exome data results. 
The intronic variant rs188978150 was validated using samples from patients 
ClinPIDD123 and ClinPIDD230. According to NGS exome data, both of the patients were 
heterozygous for the specific variant, reference allele being T and alternative allele being 
C (Figure 12). The chromatograms from Sanger-sequencing showed a Y-base on sam-
ple ClinPIDD230 (above) which proved that the patient is heterozygous for variant 
rs188978150. Based on the results it can be concluded, that the variant is in the func-
tional GBA and not its pseudogene. Reference allele T was detected homozygous in 
control sample FimmX, shown in the bottom panel of Figure 12. Also in this case the 
peak from Y-base was approximately half the height of the peak from reference base T 
in FimmX.  
 
Figure 12. Sanger-sequencing results for SNP rs188978150 from samples PID230 (above), 
PID123 (below) and FimmX control (middle). 
The results from sample ClinPIDD123 (below) showed the alternative base C instead of 
Y-base as in sample ClinPIDD230. The height of the peak appeared to be the same as 
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in FimmX, which indicated that the patient is homozygous concerning this intronic vari-
ant. The results from the validation suggest that the pseudogene is interfering with NGS 
results and the T-base, detected from data on sample ClinPIDD123 is actually located in 
the pseudogene and not in the functional GBA. According to the reference information 
of this splicing variant in HGMD, the variant reduces promoter activity by as much as 
35% but is not able to cause GD by itself. Combined with a disease-causing variant, the 
splicing variant can cause more severe phenotype of the disease [46]. As any other pos-
sibly disease-causing variants were not found from the patient, the results from the vali-
dation did not raise a cause for concern.  
The exonic variant rs75548401 was validated from samples ClinPIDD231 and 
ClinPIDD232. In the data analysis of the NGS exome data, the two patients were both 
found to be heterozygous for the specific variant, the reference allele being G. The 
Sanger-sequencing results from samples PID231 and PID232 both showed R-base in 
their chromatograms as indicated by exome data (Figure 13). R-base implies that the 
patient has a G base on one allele and an alternative base A in the other allele. The 
results shown in the figure confirmed the patients being heterozygous for variant 
rs75548401. 
 
Figure 13. Sanger-sequencing results for SNP rs75548401 from samples PID232 (above), 
PID232 (below) and FimmX control (middle). 
FimmX sample showed the reference base G in the chromatogram results (middle). The 
R-bases detected from the patient samples chromatograms had lower peaks compared 
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to the surrounding peaks, which also confirmed that both of the patients are heterozy-
gous for the particular variant. Based on the sequencing results, it can be assumed that 
the heterozygous variant is located in the functional gene instead of its pseudogene, 
GBAP1, in both of the samples. 
The rare and not yet well-known splicing variant rs555143723 was validated using sam-
ples ClinPIDD087 and ClinPIDD088. As with all the other variants, the two mentioned 
samples were both heterozygous for the variant according to the NGS exome data, ref-
erence allele being C and an alternative allele G. Figure 14 shows the chromatograms 
of the Sanger-sequencing from two samples. The sample ClinPIDD087, shown above, 
was found to be heterozygous for the specified variant, as a clear S-base was found from 
the chromatogram. S-base implies that patient is heterozygous for C and G alleles. By 
comparing the height of the peaks, the S-base was found to have a slightly lower peak 
then other peaks in the chromatograms. Especially when comparing to the clean C-base 
peak found from FimmX (middle), the S-base was approximately half of the C-base. The 
results from the control sample FimmX can be seen in the middle panel of Figure 14.  
 
Figure 14. Sanger-sequencing results for SNP rs555143723 from samples PID87 (above), 
PID88 (below) and FimmX control (middle). 
The expected S-base was not found from sample ClinPIDD088 (below). The results from 
the sequencing showed a clean C-base in the chromatogram. The peak of the base was 
the same height as other peaks in the chromatogram and also the C-base detected in 
FimmX which would suggest that the patient is in fact homozygous for the reference 
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allele and does not have the above-mentioned splicing variant. The results indicated that 
the pseudogene is, also in this case, causing false results in the exome data and that 
the variant is located in the carrier’s pseudogene.  
ClinPIDD087 was the patients sample and ClinPIDD088 was her mother’s sample. The 
results from validation indicated that the variant was inherited from the father of the pa-
tient as the mother is homozygous for the reference allele and does not carry the variant. 
For the future, it might be best to validate the variant also from the fathers sample to get 
more reassurance of the results. It is also possible that the splicing variant occurred as 
de novo. 
Exonic variant rs150466109 was validated from samples ClinPIDD343 and 
ClinPIDD235. According to the NGS exome data, the two samples were expected to be 
heterozygous for the variant. The samples had two different alternative alleles in the 
data, ClinPIDD235 had G-base as an alternative allele and ClinPIDD343 C-base. The 
reference base was T according to the data. Overall, the chromatograms had a substan-
tial amount of background that made the interpretation of the results more challenging. 
However, despite the background signal, the results could still be analyzed and can be 
seen in Figure 15.  
 
Figure 15. Sanger-sequencing results for SNP rs150466109 from samples PID343 (above), 
PID235 (middle) and FimmX control (below). 
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The chromatogram shown above from sample ClinPIDD343 was not as straightforward 
to interpret as the figure might seem at first. The chromatogram showed a Y-base that 
implied that the carrier is heterozygous regarding the variant as the exome data indi-
cated. However, the peaks surrounding the variant were lower when compared to the 
other peaks in the chromatogram, for some reason. The background peak that the soft-
ware had interpreted as C-base could be seen in all of the chromatograms, FimmX and 
ClinPID235. For that reason, the results suggested that the patient is not heterozygous 
but, on the contrary, homozygous regarding the reference allele, T.  
The results from the sample ClinPIDD235 (middle) implied that patient was also be ho-
mozygous for the reference allele. The chromatogram of the sample showed a reference 
base T instead of K base that was expected. The peak of the base was compared to T-
base from FimmX and they were found to be the same height. Also, when comparing the 
peak to other peaks in the chromatogram, the T-base was the same height as the others 
which indicates that the patients is actually homozygous for reference allele.  
Based on the validations, it can be said that the pseudogene is distorting the exome 
results on both of the samples, in this case as well. The variant was not detected in the 
functional GBA from either of the samples, but the variants are, in fact, located in exon 
3 of the pseudogene. 
The samples, in which the validation results did not correspond with the NGS exome 
data where checked visually by use of IGV [40]. The purpose of the visualization was to 
check if there were any polymorphisms at the locations where the sequencing primers 
bind. Polymorphisms at the primers locations might cause allele-specific amplification 
that could affect the analysis of the results significantly. There were not any polymor-
phisms found where the primers were located; therefore, it can be concluded that the 
validations results are valid.  
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7 Discussion 
There were some factors that caused difficulties with the thesis. First of all, when writing 
about GBA and its pseudogene GBAP1, the different databases caused some difficulties 
due to their differences in information about the specific genes. Databases and articles 
about the subject included differences in the sizes of the genes, genomic and cytogenetic 
locations and the amount of exons, which made it difficult to determine what information 
was correct and up to date. This also showed how genetics is still very much an evolving 
field of research. Especially GBA and its pseudogene, GBAP1 and their impact on GD 
is still under research. It seems that the pseudogene might have larger impact on the 
diagnostics and interpretation of disease mutations than originally thought.  
The practical part of the thesis was known to be potentially tricky from the start because 
of the difficult nature of the GBA gene. The PCR reactions had to be repeated multiple 
times to get enough product amplified. Also different programs had to be tested for dif-
ferent samples. Due to the highly diluted PCR products, there was not enough signal for 
the Sanger-sequencing and the first two sequencing reactions were mostly blank. The 
next PCR products were concentrated to improve the chances of the sequencing reac-
tion to be successful. For some reason, the forward primers worked poorly with every 
sample and significant amount of background made interpretation of the results difficult 
or impossible. It was clear that the amplification of the gene was demanding and specific 
reaction conditions needed to be applied for all the amplified fragments. 
The SiSu data was analyzed only in silico from the WEB-site due to the fact that the 
samples were not available for analysis. Therefore, validations of the variants could not 
be performed for the thesis. The data analysis seems to confirm that GDs prevalence is 
extremely rare in Finnish population as no homozygous variants were detected. Also, all 
of the heterozygous variants were quite rare and most of them had only one carrier found 
from the 10000 samples sequenced for the project. The drawback of the in silico analysis 
is that the detected variants could not be validated with another method. Some of these 
variants might actually exist in homozygous state, but the NGS data detects signals from 
both the GBA gene and its pseudogene which may influence the analysis of the sequenc-
ing results giving the impression of GBA allele heterozygosity. 
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The analysis of the SiSu data grew the study substantially wider with over 10000 Finnish 
samples. The SiSu project is currently the most extensive database of Finnish inher-
itance and with the addition of its data to the thesis, it can be said that the study gives 
quite broad picture of the frequency of possibly disease-causing mutations in the GBA 
gene in the Finnish population. 
The results from the validations clearly show that the pseudogene affects highly the NGS 
data analysis results as the pipeline does not recognize if detected the variant is located 
in the functional gene or the pseudogene. In almost half of the samples used for valida-
tions, one of the alleles could be tracked down to the pseudogene and not the functional 
GBA gene. In that aspect, the results can be considered to be fairly substantial and help-
ful for future research of the gene. The results from the validations do not cause a con-
cern regarding the patients, as all but one was found to be either heterozygous for the 
specific variant or homozygous for the reference allele. One of the patient was found to 
be homozygous for the promoter variant, but that is not concerning as the variant cannot 
cause the disease by itself, as mentioned in the results.  
Finally, based on the data analysis and validations of the findings it seems clear that 
traditional NGS is not the best method for analyzing the GBA gene as the results are not 
valid due to the pseudogenes presence. All of the heterozygous and homozygous vari-
ants found should be validated separately since even the heterozygous variant might 
actually be homozygous in the functional gene. This could happen if the pseudogene 
presents with another nucleotide than the GBA gene resulting the variant to be inter-
preted as heterozygous by the data analysis pipeline. This affects significantly the results 
if the pseudogene is not taken into account in the analysis of the data.  
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  Appendix 1 
  
Creating annotation files and using grep-command in Putty 
cd /projects/fimm_ga2_heckman/fhrb_germline 
grun.py -n fhrb_batch -c './run_samples.bash fhrb_list.txt' 
grep -w "GBA" /projects/fimm_ga2_heckman/fhrb_germline/*/*annotated.txt > /fs/pro-
jects/ms_saarela/Immunodeficiency/Clinical-exomes/GBA/FHRB_annotation 
 
